Patent License Agreement with a Vision to Improved Infertility Treatment

Unisense FertiliTech A/S receives exclusive license for use of Visible™ Discovery Platform for time-lapse assisted embryo assessment with the EmbryoScope™ Embryo Monitoring System.

Aarhus, Denmark May 26, 2009 (PressReleasePoint) Unisense FertiliTech A/S, a Danish company which has developed the
EmbryoScope™ Embryo Monitoring System for use in in-vitro fertilization (IVF), has entered into a patent license agreement with Reify Corporation, Cambridge, Massachusetts, USA.

Under the terms of the agreement, Unisense FertiliTech A/S receives an exclusive license to utilize Reify’s Visible™ Discovery Platform in the development of critical event detection and time-lapse analysis software for ooctyes and embryo development. This technology will be provided for use with the EmbryoScope™ Embryo Monitoring System, in an IVF clinical setting. Unisense FertiliTech A/S will also receive non-exclusive development rights from Reify for stem cell analysis research with defined exceptions. Under the terms of the agreement Reify receives a combination of annual guaranteed payments and royalties.

During IVF treatments, multiple oocytes are fertilized in-vitro, and the resulting embryos are grown in an incubator until they are transferred back to the patient 2 to 5 days later. A major challenge for the embryologist, is to select the best embryo with the greatest potential to result in a full-term pregnancy. Currently embryologists spend less than a few minutes over several days observing the embryos in order to minimize disruption to development.

Access to the Reify analysis algorithms will allow Unisense FertiliTech A/S to strengthen the embryo analysis function of their EmbryoScope™ Monitoring System, and facilitate time-lapse enabled embryo selection, with minimal disruption to the developing embryo.

Reify Corporation develops and markets machine vision and video analysis software-based phenotypic screens for the biotechnology and pharmaceutical industries. For more information visit their website at

Unisense FertiliTech A/S is a Danish biomedical company specialized in developing and manufacturing products for Assisted Reproductive Technology (ART). The company was founded in 2003, and is involved in international research collaborations in the area of embryo assessment and analysis with a specific focus in the IVF industry. For more information about the company, contact us at or visit our website at

Contact Info:
Unisense FertiliTech A/S
Contact person: Francesca Bahr
Sales and Marketing Manager
Office Phone: +45 89449525
Mobile Phone: +45 40255538


Press Contact:
Francesca Bahr
Brendsrupgaardsvej 21F
DK-8200 Aarhus
+45 40255538
Email partially hidden to block spam. Please use the contact form here.
Contact Francesca Bahr
Email the contact person for this press release. Do not send spam or irrelevant message.
1 + 4 =

Copy this html code to your website/blog to embed this press release.


Post new comment

2 + 0 =

To prevent automated spam submissions leave this field empty.